Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Novopharm Biotech's NOVOMAb-G2 IgM completes phase I

June 23, 1998

Russian scientists evaluate the antitumor activity of betaleukin

June 22, 1998

CBER requests additional information for Ontak BLA

June 19, 1998

ICO25 MAb suppresses tumor growth and prolongs survival in preclinical model of colon cancer

June 19, 1998

New dosing regimen of Avax melanoma vaccine results in improved outcome

June 17, 1998

Biomira and Chiron expand Theratope cancer vaccine agreement

June 17, 1998

Combination immunotherapy of renal cell carcinoma: efficacy established in phase II trial

June 11, 1998

Excellent phase III results reported for bropirimine in CIS

June 11, 1998

Encouraging results reported for Cel-Sci's Multikine

June 11, 1998

Immunex's CD40 Ligand enters phase I

June 10, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...